Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted protein degradation therapies. Its platform is designed to selectively eliminate disease-causing proteins, with programs spanning immunology and oncology and a business model centered on internal R&D plus collaborations such as its Sanofi partnership.

−869,9 %

−794,0 %

−16,7 %

10.47

— Kymera Therapeutics, Inc.
	%
Targeted protein degradation platform	0% Internal discovery engine used to identify degraders that remove disease-driving proteins.
Collaboration revenue	100% Research and development services performed under partnered programs, including Sanofi.
Clinical-stage pipeline	0% Drug candidates advancing through preclinical and clinical development in immunology and oncology.

Kymera does not sell approved drugs today; its current customers are collaboration partners that fund research and...

Pharmaceutical collaboration partnersprimary
Partners such as Sanofi fund research services and joint development programs to access Kymera's platform and pipeline.
Future prescribers and treatment centersemerging
Physicians, hospitals, and specialty clinics would use approved therapies if the pipeline reaches commercialization.
Third-party payorsemerging
Government and private insurers would reimburse approved products and strongly influence adoption and pricing.

Kymera is headquartered in Watertown, Massachusetts, and its core research and administrative operations are based in...

•Headquartered in Watertown, Massachusetts
•Core labs and offices are in the United States
•Clinical trials are outsourced to CROs across relevant markets
•Certain drug manufacturing is outsourced to contract manufacturers
•No country-level revenue disclosure in the excerpts

Kymera’s strategy is to expand its targeted protein degradation platform, advance its pipeline, and secure regulatory...

Advance lead programs and broaden the pipelineshort-term

Clinical and preclinical progress is the main value driver for a clinical-stage biotech.

Leverage collaborations to fund developmentshort-term

Partnerships provide non-dilutive capital and external validation while reducing funding pressure.

Maintain capital runway and optionalitymedium-term

The company must finance long development timelines before product sales begin.

Build commercialization readiness selectivelymedium-term

If a candidate is approved, Kymera may need sales, marketing, reimbursement and supply capabilities.

Kymera is a clinical-stage biotech with no product sales, so its value depends on successful development, regulatory...

critical

Clinical development failure

Pipeline value depends on safety, tolerability, and efficacy in trials.

Scope: Lead programs and future candidates
Materiality: high

high

Regulatory approval risk

The company cannot generate product sales without FDA or foreign approvals.

Scope: All product candidates
Materiality: high

high

Capital dilution and financing risk

Operations require substantial funding before commercialization.

Scope: Equity raises, debt, collaborations
Materiality: high

high

Competitive pressure

Large pharma and biotech peers are pursuing similar degrader and target programs.

Scope: Targeted protein degradation, STAT6 and related programs
Materiality: high

medium

Outsourcing and supply chain dependence

Clinical trials and manufacturing are largely performed by third parties.

Scope: CROs and contract manufacturers
Materiality: medium

Collaboration revenue recognition

Affects quarterly collaboration revenue, especially Sanofi-related revenue

Research and development expense timing

Drives operating loss volatility

Lease accounting

Affects right-of-use assets, lease liabilities, and occupancy expense

Impairment of long-lived assets

Potential non-cash charges to earnings

Kymera Therapeutics, Inc.

Clinical development failure

Regulatory approval risk

Capital dilution and financing risk

Competitive pressure

Outsourcing and supply chain dependence

KIORA PHARMACEUTICALS INC

Kyverna Therapeutics, Inc.

C4 Therapeutics, Inc.

Aprea Therapeutics, Inc.

Damora Therapeutics, Inc.

Bicara Therapeutics Inc.